NIC 002

Drug Profile

NIC 002

Alternative Names: Anti-nicotine immunotherapy - Cytos; Anti-nicotine virus-like particle vaccine - Cytos; CYT002-NicQβ; Immunodrug™ nicotine addiction vaccine - Cytos/Novartis; NIC002 vaccine; Nicotine-Qβ

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytos Biotechnology
  • Developer Cytos Biotechnology; Duke University; Wake Forest University School of Medicine
  • Class Smoking cessation therapies; Vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Smoking withdrawal

Most Recent Events

  • 23 Jan 2013 Novartis terminates its worldwide licence for NIC 002 and rights will revert back to Cytos Biotechnology
  • 31 Dec 2010 Phase-II clinical trials in Smoking withdrawal in USA (SC)
  • 21 Sep 2010 Phase II development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top